Leveraging fluorinated glucosamine action to boost antitumor immunity

Current Opinion in Immunology

Volumn 25, Issue 2, 2013, Pages 206-213

  Dimitroff, Charles J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACETAMIDO 2,4 DIDEOXY 1,3,6 TRI O ACETYL 4 FLUOROGLUCOPYRANOSE; GALECTIN 1; GLUCOSAMINE DERIVATIVE; GLYCAN DERIVATIVE; MEMBRANE PROTEIN; N ACETYLLACTOSAMINE; N ACETYLLACTOSAMINYL GLYCAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL PROTECTION; EFFECTOR CELL; HUMAN; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; GLUCOSAMINE; HALOGENATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84877055284     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.11.003     Document Type: Review

References (64)

1. Bernacki R., Porter C., Korytnyk W., Mihich E. Plasma membrane as a site for chemotherapeutic intervention. Adv Enzyme Regul 1977, 16:217-237.
2. Bernacki R.J., Sharma M., Porter N.K., Rustum Y., Paul B., Korythyk W. Biochemical characteristics, metabolism, and antitumor activity of several acetylated hexosamines. J Supramol Struct 1977, 7:235-250.
3. Sharma M., Bernacki R.J., Paul B., Korytnyk W. Fluorinated carbohydrates as potential plasma membrane modifiers. Synthesis of 4- and 6-fluoro derivatives of 2-acetamido-2-deoxy-d-hexopyranoses. Carbohydr Res 1990, 198:205-221.
4. Dimitroff C.J., Pera P., Dall'Olio F., Matta K.L., Chandrasekaran E.V., Lau J.T., Bernacki R.J. Cell surface n-acetylneuraminic acid alpha2,3-galactoside-dependent intercellular adhesion of human colon cancer cells. Biochem Biophys Res Commun 1999, 256:631-636.
5. Dimitroff C.J., Sharma A., Bernacki R.J. Cancer metastasis: a search for therapeutic inhibition. Cancer Invest 1998, 16:279-290.
6. Skrincosky D.M., Allen H.J., Bernacki R.J. Galaptin-mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptin-binding glycoproteins. Cancer Res 1993, 53:2667-2675.
7. Woynarowska B., Dimitroff C.J., Sharma M., Matta K.L., Bernacki R.J. Inhibition of human HT-29 colon carcinoma cell adhesion by a 4-fluoro-glucosamine analogue. Glycoconj J 1996, 13:663-674.
8. Woynarowska B., Skrincosky D.M., Haag A., Sharma M., Matta K., Bernacki R.J. Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs. J Biol Chem 1994, 269:22797-22803.
9. Bresalier R.S., Byrd J.C., Brodt P., Ogata S., Itzkowitz S.H., Yunker C.K. Liver metastasis and adhesion to the sinusoidal endothelium by human colon cancer cells is related to mucin carbohydrate chain length. Int J Cancer 1998, 76:556-562.
10. Gangopadhyay A., Lazure D.A., Thomas P. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells. Clin Exp Metastasis 1998, 16:703-712.
11. Gout S., Tremblay P.L., Huot J. Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis 2008, 25:335-344.
12. Irimura T., Ota M., Kawamura Y., Nemoto-Sasaki Y. Carbohydrate-mediated adhesion of human colon carcinoma cells to human liver sections. Adv Exp Med Biol 2001, 491:403-412.
13. Kitakata H., Nemoto-Sasaki Y., Takahashi Y., Kondo T., Mai M., Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002, 62:6682-6687.
14. Kruskal J.B., Azouz A., Korideck H., El-Hallak M., Robson S.C., Thomas P., Goldberg S.N. Hepatic colorectal cancer metastases: imaging initial steps of formation in mice. Radiology 2007, 243:703-711.
15. Opolski A., Laskowska A., Madej J., Wietrzyk J., Klopocki A., Radzikowski C., Ugorski M. Metastatic potential of human CX-1 colon adenocarcinoma cells is dependent on the expression of sialosyl Le(a) antigen. Clin Exp Metastasis 1998, 16:673-681.
16. St Hill C.A., Farooqui M., Mitcheltree G., Gulbahce H.E., Jessurun J., Cao Q., Walcheck B. The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas. BMC Cancer 2009, 9:79.
17. Tsuiji H., Nakatsugawa S., Ishigaki T., Irimura T. Malignant and other properties of human colon carcinoma cells after suppression of sulfomucin production in vitro. Clin Exp Metastasis 1999, 17:97-104.
18. Weston B.W., Hiller K.M., Mayben J.P., Manousos G.A., Bendt K.M., Liu R., Cusack J.C. Expression of human alpha(1,3)fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells. Cancer Res 1999, 59:2127-2135.
19. Dimitroff C.J., Bernacki R.J., Sackstein R. Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood 2003, 101:602-610.
20. Dimitroff C.J., Kupper T.S., Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003, 112:1008-1018.
21. Descheny L., Gainers M.E., Walcheck B., Dimitroff C.J. Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand. J Invest Dermatol 2006, 126:2065-2073.
22. Gainers M.E., Descheny L., Barthel S.R., Liu L., Wurbel M.A., Dimitroff C.J. Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J Immunol 2007, 179:8509-8518.
23. Marathe D.D., Buffone A., Chandrasekaran E.V., Xue J., Locke R.D., Nasirikenari M., Lau J.T., Matta K.L., Neelamegham S. Fluorinated per-acetylated GalNAc metabolically alters glycan structures on leukocyte PSGL-1 and reduces cell binding to selectins. Blood 2010, 115:1303-1312.
24. Perillo N.L., Pace K.E., Seilhamer J.J., Baum L.G. Apoptosis of T cells mediated by galectin-1. Nature 1995, 378:736-739.
25. Cedeno-Laurent F., Barthel S.R., Opperman M.J., Lee D.M., Clark R.A., Dimitroff C.J. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol 2010, 185:4659-4672.
26. Cedeno-Laurent F., Opperman M., Barthel S.R., Kuchroo V.K., Dimitroff C.J. Galectin-1 triggers an immunoregulatory signature in th cells functionally defined by IL-10 expression. J Immunol 2012, 188:3127-3137.
27. Cedeno-Laurent F., Watanabe R., Teague J.E., Kupper T.S., Clark R.A., Dimitroff C.J. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 2012, 119:3534-3538.
28. Ilarregui J.M., Croci D.O., Bianco G.A., Toscano M.A., Salatino M., Vermeulen M.E., Geffner J.R., Rabinovich G.A. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009, 10:981-991.
29. Toscano M.A., Bianco G.A., Ilarregui J.M., Croci D.O., Correale J., Hernandez J.D., Zwirner N.W., Poirier F., Riley E.M., Baum L.G., et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007, 8:825-834.
30. van der Leij J., van den Berg A., Blokzijl T., Harms G., van Goor H., Zwiers P., van Weeghel R., Poppema S., Visser L. Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response. J Pathol 2004, 204:511-518.
31. Barthel S.R., Antonopoulos A., Cedeno-Laurent F., Schaffer L., Hernandez G., Patil S.A., North S.J., Dell A., Matta K.L., Neelamegham S., et al. Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation. J Biol Chem 2011, 286:21717-21731.
32. Barthel S.R., Gavino J.D., Wiese G.K., Jaynes J.M., Siddiqui J., Dimitroff C.J. Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology 2008, 18:806-817.
33. Barthel S.R., Wiese G.K., Cho J., Opperman M.J., Hays D.L., Siddiqui J., Pienta K.J., Furie B., Dimitroff C.J. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci USA 2009, 106:19491-19496.
34. Dimitroff C.J., Descheny L., Trujillo N., Kim R., Nguyen V., Huang W., Pienta K.J., Kutok J.L., Rubin M.A. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res 2005, 65:5750-5760.
35. Dimitroff C.J., Lechpammer M., Long-Woodward D., Kutok J.L. Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. Cancer Res 2004, 64:5261-5269.
36. Nishimura S.I., Hato M., Hyugaji S., Feng F., Amano M. Glycomics for drug discovery: metabolic perturbation in androgen-independent prostate cancer cells induced by unnatural hexosamine mimics. Angew Chem Int Ed Engl 2012, 124:1-6.
37. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
38. Mihm M.C., Clemente C.G., Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996, 74:43-47.
39. Oble D.A., Loewe R., Yu P., Mihm M.C. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009, 9:3.
40. Liakou C.I., Narayanan S., Ng Tang D., Logothetis C.J., Sharma P. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 2007, 7:10.
41. Besser M.J., Shapira-Frommer R., Treves A.J., Zippel D., Itzhaki O., Hershkovitz L., Levy D., Kubi A., Hovav E., Chermoshniuk N., et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010, 16:2646-2655.
42. Dudley M.E., Gross C.A., Langhan M.M., Garcia M.R., Sherry R.M., Yang J.C., Phan G.Q., Kammula U.S., Hughes M.S., Citrin D.E., et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010, 16:6122-6131.
43. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-5239.
44. Vereecken P., Awada A., Suciu S., Castro G., Morandini R., Litynska A., Lienard D., Ezzedine K., Ghanem G., Heenen M. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 2009, 19:316-320.
45. Radosavljevic G., Jovanovic I., Majstorovic I., Mitrovic M., Lisnic V.J., Arsenijevic N., Jonjic S., Lukic M.L. Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis 2011, 28:451-462.
46. Mourad-Zeidan A.A., Melnikova V.O., Wang H., Raz A., Bar-Eli M. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 2008, 173:1839-1852.
47. Rodig S.J., Ouyang J., Juszczynski P., Currie T., Law K., Neuberg D.S., Rabinovich G.A., Shipp M.A., Kutok J.L. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res 2008, 14:3338-3344.
48. Juszczynski P., Ouyang J., Monti S., Rodig S.J., Takeyama K., Abramson J., Chen W., Kutok J.L., Rabinovich G.A., Shipp M.A. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007, 104:13134-13139.
49. Gandhi M.K., Moll G., Smith C., Dua U., Lambley E., Ramuz O., Gill D., Marlton P., Seymour J.F., Khanna R. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007, 110:1326-1329.
50. Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., Mordoh J., Fainboim L., Podhajcer O.L., Rabinovich G.A. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5:241-251.
51. Weishaupt C., Munoz K.N., Buzney E., Kupper T.S., Fuhlbrigge R.C. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007, 13:2549-2556.
52. Cedeno-Laurent F., Opperman M.J., Barthel S.R., Hays D., Schatton T., Zhan Q., He X., Matta K.L., Frank M.H., Supko J.G., et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates anti-tumor immunity. J Invest Dermatol 2012, 132:410-420.
53. Cedeno-Laurent F., Dimitroff C.J. Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj J 2012, 29:619-625.
54. Rabinovich G.A., Croci D.O. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012, 36:322-335.
55. Rabinovich G.A., Vidal M. Galectins and microenvironmental niches during hematopoiesis. Curr Opin Hematol 2012, 18:443-451.
56. Sackstein R. The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives. Curr Opin Hematol 2011, 18:239-248.
57. Winkler I.G., Snapp K.R., Simmons P.J., Levesque J.P. Adhesion to E-selectin promotes growth inhibition and apoptosis of human and murine hematopoietic progenitor cells independent of PSGL-1. Blood 2004, 103:1685-1692.
58. Butler M.O., Ansen S., Tanaka M., Imataki O., Berezovskaya A., Mooney M.M., Metzler G., Milstein M.I., Nadler L.M., Hirano N. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol 2010, 22:863-873.
59. Butler M.O., Friedlander P., Milstein M.I., Mooney M.M., Metzler G., Murray A.P., Tanaka M., Berezovskaya A., Imataki O., Drury L., et al. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 2011, 3:80ra34.
60. Butler M.O., Lee J.S., Ansen S., Neuberg D., Hodi F.S., Murray A.P., Drury L., Berezovskaya A., Mulligan R.C., Nadler L.M., et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 2007, 13:1857-1867.
61. Jin H.T., Anderson A.C., Tan W.G., West E.E., Ha S.J., Araki K., Freeman G.J., Kuchroo V.K., Ahmed R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010, 107:14733-14738.
62. Sharma S., Sundararajan A., Suryawanshi A., Kumar N., Veiga-Parga T., Kuchroo V.K., Thomas P.G., Sangster M.Y., Rouse B.T. T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci USA 2011, 108:19001-19006.
63. Jiang X., Clark R.A., Liu L., Wagers A.J., Fuhlbrigge R.C., Kupper T.S. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 2012, 483:227-231.
64. Kupper T.S. Old and new: recent innovations in vaccine biology and skin T cells. J Invest Dermatol 2012, 132:829-834.